Wentworth Kory James's Form 4/A amendment
AmendedEntrada Therapeutics, Inc. (TRDA) · filed Apr 19, 2023
- Accession no.
- 0001689375-23-000028
- Filed
- Apr 19, 2023
- Trade date
- Mar 1, 2023
- Filing delay
- 49 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Mar 3, 2023
This filing lists 1 non-derivative transaction and 1 derivative transaction. It carries over 3 transactions from the original filing that it did not restate. Open-market sales total $18.4K. It was filed 49 days after the trade.
This amendment restates part of 0001689375-23-000015 (filed Mar 3, 2023). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wentworth Kory JamesCIK 0001725663 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | Common Stock | AGrant or awardAcquired | +14,200 | $0.00 | $0 | 27,957 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | Common Stock | AGrant or awardAcquired | +21,500 | $0.00 | $0 | 21,500 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001689375-23-000015 (filed Mar 3, 2023).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Common Stock | FTax withholdingDisposed | −1,005 | $11.60 | −$11,658 | 43,904 | Direct | |
| Mar 2, 2023 | Common Stock | SSaleDisposed | −1,602 | $10.46F4 | −$16,756.92 | 42,302 | Direct | |
| Mar 2, 2023 | Common Stock | SSaleDisposed | −145 | $11.23F5 | −$1,628.35 | 42,157 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.03 to $10.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.345, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
- F2
The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively.
- F3
25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027.
Remarks
This Form 4A is only to correct the reported amount to beneficial ownership of the Reporting Person.